Summary
Thrombomodulin (TM) is a cell membrane-bound glycoprotein that functions as a thrombin
cofactor in the activation of protein C. Its protein structure includes a N-terminal
lectin-like domain (D1), 6 epidermal growth factor repeats (D2), a serine-threonine-rich
region (D3), a transmembrane domain (D4) and a short cytoplasmic tail (D5). Recent
studies have demonstrated the direct effect ofTM on cellular proliferation, adhesion
and inflammation. In the study, we investigated the role of TM in vascular remodeling
and neointima formation in a mouse carotid ligation model. TM expressions on the endothelium,
neointima and media were examined in the ligated carotid artery by immunohistochemistry
and quantitative real-time reverse transcription PCR. Endothelial TM expression decreased
after ligation and appeared later in the media and neointima, which is quite similar
to the appearance of TM in the human atherosclerotic process. Recombinant TMD123 was
prepared. It was effective for thrombin-dependent protein C activation and the inhibition
of leukocyte adhesion to the vessel wall after carotid ligation. RecombinantTMD123
and saline was administered immediately before and after carotid ligation. The TM-treated
arteries demonstrated significantly less arterial dilatation (30279±12605 vs 73789±15073
µm2, p<0.05) in response to less neointima formation (14179±6538 vs 42227±8754 µm2, p<0.05) at 4 weeks after ligation. Our data indicated that there was a compensatory
increase inTM expression in the media and neointima in relation to the reduced endothelial
TM after carotid ligation. Early recombinant TM treatment in mice undergoing carotid
ligation altered vascular remodeling and decreased the severity of neointima formation.
Keywords
Thrombomodulin - atherosclerosis - neointima